MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

NCT00602329 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Due to Poor accrual

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: fluorouracil
DRUG: leucovorin calcium
DRUG: oxaliplatin

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]